期刊文献+

炎症性肠病患者艰难梭菌感染的流行情况及危险因素研究 被引量:4

Prevalence and risk factors of Clostridium difficile infection in patients with inflammatory bowel disease
下载PDF
导出
摘要 目的研究炎症性肠病(IBD)患者艰难梭菌感染的流行情况及危险因素,为临床治疗提供依据。方法将2017年11月至2019年6月于广州中山大学附属第一医院入院的130例炎症性肠病患者纳入研究。根据患者IBD诊断,将患者分为克罗恩病组(CD)和溃疡性结肠炎组(UC),收集其入院48 h内粪便标本。采用免疫荧光法检测谷氨酸脱氢酶(GDH)、艰难梭菌A/B毒素(CDAB),实时荧光PCR法检测粪便艰难梭菌毒素B基因(tcdB),显色培养法检测艰难梭菌,根据艰难梭菌检测结果与患者临床情况,将患者分为阴性组、定植组和感染组,比较CD和UC两组间各项指标差异和四种检测方法的检测结果。结果在130例炎症性肠病患者中,克罗恩病组(CD)和溃疡性结肠炎组(UC)例数分别为80(61.5%)和50(38.5%);CD组艰难梭菌定植率和感染率分别为20.0%(16/80)和8.8(7/80)%;溃疡性结肠炎定植率和感染率分别为16.0%(8/50)和26.0%(13/50);两组间一般情况、大便检测情况与炎症标志物中多项指标比较,差异有统计学意义(P<0.05)。显色培养法、免疫荧光法检测GDH、CDAB、PCR法检测tcdB的阳性率分别为29.2%、29.2%、3.1%和20.8%。粪便艰难梭菌毒素B基因一步法检测艰难梭菌感染与指南推荐联合法结果比较,差异无统计学意义(P>0.05)。结论 UC患者比CD患者更容易感染艰难梭菌;需要重视IBD患者的艰难梭菌定植情况。 Objectives To study the prevalence and risk factors of Clostridium difficile infection in patients with inflammatory bowel disease(IBD) to provide a basis for clinical treatment.Method 130 patients with inflammatory bowel disease admitted to the First Affiliated Hospital of Sun Yat-sen University in Guangzhou from November 2017 to June 2019 were included in the study.According to the diagnosis of IBD,the patients were divided into Crohn’s disease group(CD) and ulcerative colitis group(UC),and stool samples were collected within 48 hours of admission.which The Chromogenic culture,toxin A/B enzyme immunoassay(CD AB),glutamate dehydrogenase enzyme immunoassay(GDH) and real-time fluorescent quantitative PCR detection of gene for toxin B(tcdB) were used to detect Clostridium difficile.According to the test results of Clostridium difficile and the clinical conditions of the patients,the patients were divided into negative group,colonization group and infection group,and the differences in various indicators between the CD and UC groups and the test results of the four detection methods were compared.Result Among 130 patients with IBD,the numbers of Crohn’s disease group(CD) and ulcerative colitis group(UC) were 80(61.5%) and 50(38.5%),respectively.The colonization rate and infection rate of Clostridium difficile in the CD group were20.0%(16/80) and 8.8(7/80) %,respectively.The colonization rate and infection rate in ulcerative colitis were 16.0%(8/50) and 26.0%(13/50) respectively.There were significant differences between the two groups in general conditions,stool detection conditions and multiple indicators of inflammation markers(P<0.05).The positive rates of chromogenic culture method,immunofluorescence method to detect GDH,CDAB,and qRT-PCR method to detect tcdB were 29.2%,29.2%,3.1% and 20.8%,respectively.There was no statistically significant difference between the results of one-step detection of Clostridium difficile toxin B gene in fecal C.difficile infection and the combined method recommended by the guidelines(P>0.05).Concl-?sions UC patients are more likely to be infected with C.difficile than CD patients.Attention should be paid to the colonization of C.difficile in patients with IBD.
作者 伍众文 刘平娟 郭鹏豪 陈怡丽 廖康 黄彬 WU Zhongwen;LIU Pingjuan;GUO Penghao;CHEN Yili;LIAO Kang;HUANG Bin(Department of Clinical Laboratory,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou,Guangdong,China,510080)
出处 《分子诊断与治疗杂志》 2021年第9期1381-1384,1389,共5页 Journal of Molecular Diagnostics and Therapy
基金 广东省自然科学基金(2021A1515010423)。
关键词 炎症性肠病 艰难梭菌 定植 感染 危险因素 Inflammatory Bowel Disease Clostridium difficile asymptomatic carriage Clostridium difficile infection risk factors
  • 相关文献

参考文献4

二级参考文献59

  • 1梁光军,赵李祥,杨旭芹,贾红,张小荣,文其乙,刘秀梵.应用多重PCR方法鉴定粪样和食品中分离的产气荚膜梭菌[J].中国人兽共患病杂志,2005,21(5):420-423. 被引量:14
  • 2Rupnik M, Wilcox M H, Gerding D N. Clostridium difficile infection: new developments in epidemiology and pathogenesis[J]. Nat Rev Microbiol, 2009, 7(7): 526-536.
  • 3Zucca M, Scutera S, Savoia D. Novel avenues for Clostridium difficile infection drug discovery[J]. Expert Opin Drug Discov, 2013,8(4): 459-477.
  • 4Rolfe R D, Finegold S M. Clostridium difficile: its role in intestinal disease[M]. San Diego: Academic Press, 1988.
  • 5Bishara J, Bloch Y, Garty M, et al. Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israe1[J]. Diagn Microbiol Infect Dis, 2006,54(2): 141-144.
  • 6Pelaez T, Alcala I, Alonso R, et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin[J]. Antimicrob Agents Chemother, 2002, 46(6): 1647-1650.
  • 7Johnson S, Sanchez J L, Gerding D N. Metronidazole resistance in Clostridium difficile[J]. Clin Infect Dis, 2000, 31(2): 625-626.
  • 8Pelaez T, Cercenado E, Alcala L, et al. Metronidazole resistance in Clostridium difficile is heterogeneous[J]. J Clin Microbiol, 2008, 46(9): 3028-3032.
  • 9Louie T J, Miller M A, Mullane K M, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection[J]. N Engl J Med, 2011, 364(5): 422-431.
  • 10Wilcox M H, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin[J]. J Antimicrob Chemother, 1995,36(4): 673-679.

共引文献135

同被引文献49

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部